<DOC>
	<DOC>NCT02378688</DOC>
	<brief_summary>The primary objectives of the study are: - To evaluate the safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD） - To evaluate the clinical efficacy of MT-1303 in subjects with moderate to severe active CD.</brief_summary>
	<brief_title>Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis of CD (involving small intestine and/or colon), confirmed by both endoscopy and histopathology at least 3 months prior to Visit 1 Previous use of any type of corticosteroids or immunosuppressants for the treatment of CD Moderate to severe active CD defined by a CDAI score of ≥220 to ≤450 points at Visit 1 Diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis or coeliac disease Enterocutaneous, abdominal or pelvic active fistulae, abscesses or fistulae likely to require surgery during the study GI surgery (including appendectomy) within 12 weeks prior to Visit 2 (Baseline) or has surgery planned or deemed likely to require surgery for CD during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>